Ligand Pharma (LGND) Misses Q1 EPS by 6c, Miss on Revenues; Light FY17 Guidance

Ligand Pharma (NASDAQ: LGND) reported Q1 EPS of $0.57, $0.06 worse than the analyst estimate of $0.63. Revenue for the quarter came in at $29.6 million versus the consensus estimate of $31.24 million.

GUIDANCE:

Ligand Pharma sees FY2017 EPS of $2.70, versus the consensus of $2.71. Ligand Pharma sees FY2017 revenue of $130 million, versus the consensus of $133.9 million.

For earnings history and earnings-related data on Ligand Pharma (LGND) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Pfizer lung cancer drug misses survival goal in Phase 3 trial
• C.H. Robinson acquires DeSpir Logistics for $75 million